Type 2 Diabetes Prevention Across the Life Course
Rather than intervening when dysglycemia is established, prevention efforts should focus on prediabetes remission and restoration of normoglycemia. Here the authors call for a new agenda informed by mechanistic heterogen
The management of type 2 diabetes has traditionally focused on treating established disease rather than preventing its onset. However, this approach may be misguided as it does not address the root causes of the condition. Instead, research suggests that prevention efforts should focus on prediabetes remission and restoration of normoglycemia. This shift in perspective is driven by a growing understanding of the complex interplay between genetic, environmental, and lifestyle factors that contribute to the development of type 2 diabetes. By adopting a life-course risk architecture approach, which considers the cumulative impact of these factors across an individual's lifetime, researchers can identify high-risk populations and develop targeted interventions. Furthermore, advances in precision medicine offer scalable tools for personalized treatment strategies, enabling healthcare providers to tailor their approaches to individual patient needs. The development of novel therapeutic agents, including peptides, holds promise for the prevention and treatment of type 2 diabetes. However, it is essential to note that these agents are intended for research use only (RUO) and should not be used in clinical practice without proper authorization and regulatory oversight.